What Makes Retatrutide a Triple Agonist
Retatrutide is an investigational peptide engineered to activate three metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Early and mid-stage randomized trials have studied how this combined signaling affects body weight and glycemic measures in adults with obesity or type 2 diabetes.
What is Retatrutide?
Retatrutide, previously identified as LY3437943, is a single peptide developed to act as an agonist at the GIP, GLP-1, and glucagon receptors. It has been evaluated as a once-weekly subcutaneous investigational treatment in randomized clinical trials involving adults with obesity and adults with type 2 diabetes. This page describes the published research and does not present retatrutide as an approved therapy or an established clinical protocol.
How does it work?
The three targeted receptors have complementary metabolic roles. GLP-1 and GIP receptor signaling can influence glucose-dependent insulin secretion, appetite, and food intake. Glucagon receptor signaling can affect hepatic glucose production and energy expenditure. Retatrutide combines activity at all three receptors in one molecule; clinical trials are testing whether that combined mechanism can improve weight and metabolic outcomes while maintaining an acceptable safety profile.
The clinical case for Retatrutide.
Body Weight Outcomes
In a randomized phase 2 obesity trial, retatrutide produced dose-dependent reductions in body weight over 48 weeks compared with placebo. These findings describe a controlled research setting and do not establish a self-directed treatment protocol.
Glycemic Outcomes
A randomized phase 2 trial in adults with type 2 diabetes found improvements in glycated hemoglobin and body weight across retatrutide dose groups. The study compared retatrutide with placebo and dulaglutide while monitoring safety and tolerability.
A Distinct Triple-Receptor Strategy
Unlike single GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, retatrutide was designed to add glucagon receptor activity. The clinical significance of this three-receptor profile continues to be evaluated in controlled trials.
The Science Behind Retatrutide
Retatrutide's defining feature is balanced agonist activity across GIP, GLP-1, and glucagon receptors. The phase 1b trial established early pharmacodynamic, glycemic, weight, and tolerability observations in people with type 2 diabetes. Separate phase 2 trials then evaluated the molecule in adults with type 2 diabetes and in adults with obesity. Across these studies, gastrointestinal events were among the most commonly reported adverse effects and were more frequent during dose escalation. The obesity trial also reported dose-dependent increases in heart rate that peaked during treatment and later declined. These results support continued investigation, but they should not be read as evidence for unrelated claims involving tissue repair, neuroprotection, skin aging, or joint pain.
Backed by peer-reviewed research. Framed for the practicing clinician.
Clinician questions on Retatrutide.
Retatrutide is called a triple agonist because one peptide activates GIP, GLP-1, and glucagon receptors. This differs from medicines designed to act on only GLP-1 or on the GIP and GLP-1 receptor pair.
Published randomized trials have evaluated outcomes including body-weight change, glycated hemoglobin, fasting glucose, safety, and tolerability in adults with obesity or type 2 diabetes.
Gastrointestinal adverse events were commonly reported, particularly during dose escalation. The phase 2 obesity trial also reported dose-dependent increases in heart rate that peaked and then declined. Trial eligibility, monitoring, and dose escalation are important context for these findings.
No. This is an educational summary of published research. It does not provide individualized medical advice, prescribing instructions, or an established Retatrutide treatment protocol.
No. Retatrutide remains a subject of clinical research, and this page summarizes published evidence rather than providing prescribing instructions. Our separate Peptide Dosing Guide & Clinical Calculator explains general educational principles clinicians use when evaluating peptide dosing, titration, reconstitution, and administration.
Want the full clinical picture on Retatrutide?
Unlock every molecule, dosing protocol, and live class inside Inner Circle membership.
Continue exploring the library.
Semaglutide
Take a comprehensive approach to your health goals with Semaglutide, a GLP-1 analog that encourages insulin production and decreases appetit…
Cerebrolysin
Cerebrolysin is a peptide-based neurotrophic agent that supports brain health and cognitive function. It is studied for its potential to tre…
CJC-1295
CJC-1295 is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog, stimulating the release of growth hormone in …
Tirzepatide
Tirzepatide combines both the Semaglutide properties along with a GIP receptor that helps the body control blood sugar levels and helps you …
- Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine (2023).
- Rosenstock et al. Retatrutide for People with Type 2 Diabetes: A Randomised Phase 2 Trial. The Lancet (2023).
- Urva et al. LY3437943, a Triple GIP, GLP-1 and Glucagon Receptor Agonist in Type 2 Diabetes: A Phase 1b Trial. The Lancet (2022).